Vivelle-Dot

Atrophic Vaginitis, Low Testosterone, Hypogonadism + 27 more
Treatment
5 FDA approvals
20 Active Studies for Vivelle-Dot

What is Vivelle-Dot

EstradiolThe Generic name of this drug
Treatment SummaryEstradiol is a naturally occurring hormone that is used in hormone therapy products to treat conditions related to low estrogen, such as vaginal dryness and hot flashes. It is available in multiple forms, including oral tablets, injections, vaginal rings, patches, sprays, gels, and creams. To increase its effectiveness when taken orally or injected, estradiol is usually combined with an ester side-chain. One common form of estradiol is ethinyl estradiol (EE), which is the estrogenic component of most combination birth control pills. EE has a higher bioavailability and is less susceptible to metabolism than est
Estradermis the brand name
image of different drug pills on a surface
Vivelle-Dot Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Estraderm
Estradiol
1986
373

Approved as Treatment by the FDA

Estradiol, also known as Estraderm, is approved by the FDA for 5 uses like Birth Control and Hormonal Contraception .
Birth Control
Used to treat Contraception in combination with Levonorgestrel
Hormonal Contraception
Used to treat Hormonal Contraception therapy in combination with Levonorgestrel
Breast Cancer
Palliative Treatment
Breast Cancer

Effectiveness

How Vivelle-Dot Affects PatientsEstradiol helps to reduce symptoms of hot flashes, vaginal dryness, and pain during sex. It can also help to increase bone density, reduce harmful cholesterol levels, and increase levels of certain proteins in the liver. Taking estradiol may increase the risk of stroke, blood clots, and high blood pressure. It may also cause the body to become more likely to form blood clots, which is seen during both pregnancy and when taking certain birth control pills. The increased risk of high blood pressure is likely caused by estradiol causing the body to retain more sodium.
How Vivelle-Dot works in the bodyEstrogen is a hormone found in many of the body's tissues, including the skin, breast, uterus, and brain. In adult women during their reproductive years, the ovarian follicle produces most of the estrogen in the body. After menopause, however, the majority of estrogen is made when androstenedione (a hormone from the adrenal cortex) is converted to estrone in other tissues. Estrone is not as potent as estradiol, the main form of estrogen in premenopausal women, and can cause unpleasant symptoms such as hot flashes and mood swings. When estradiol binds to specific

When to interrupt dosage

The recommended dosage of Vivelle-Dot is contingent upon the established condition, such as Premature Menopause, Pharmaceutical Preparations and Postmenopause. The amount of dosage depends on the method of delivery featured in the table below.
Condition
Dosage
Administration
Atrophic
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Vasomotor System
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Hormonal Contraception
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Balanitis Xerotica Obliterans
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Prostate Cancer
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Pharmaceutical Preparations
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
female castration
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
estradiol
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Breast
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Therapeutic procedure
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
moderate to severe symptoms
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Amenorrhea
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Low Testosterone
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Hypogonadism
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Osteoporosis
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Urogenital atrophy
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
hypoestrogenism
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Prostatic Neoplasms
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Hormone Replacement Therapy
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Hysterectomy
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Warnings

Vivelle-Dot Contraindications
Condition
Risk Level
Notes
Breast
Do Not Combine
Angioedema
Do Not Combine
Venous Thrombosis
Do Not Combine
undiagnosed abnormal genital bleeding
Do Not Combine
estrogen-dependent neoplasia
Do Not Combine
Liver Dysfunction
Do Not Combine
Breast
Do Not Combine
suspected pregnancy
Do Not Combine
Breast Cancer
Do Not Combine
Pulmonary Embolism
Do Not Combine
Angioedema
Do Not Combine
Deep Vein Thrombosis
Do Not Combine
Thromboembolism
Do Not Combine
Neoplasms, Hormone-Dependent
Do Not Combine
Pulmonary Embolism
Do Not Combine
Thromboembolism
Do Not Combine
Thrombophilia
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Estradiol may interact with Pulse Frequency
There are 20 known major drug interactions with Vivelle-Dot.
Common Vivelle-Dot Drug Interactions
Drug Name
Risk Level
Description
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Estradiol.
Anagrelide
Major
The metabolism of Anagrelide can be decreased when combined with Estradiol.
Anastrozole
Major
The therapeutic efficacy of Anastrozole can be decreased when used in combination with Estradiol.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Estradiol.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Estradiol.
Vivelle-Dot Toxicity & Overdose RiskAfter 90 days, the highest safe dose of estradiol in rats was found to be 0.003 mg/kg/day. If taken in high amounts, estradiol can cause nausea, vomiting, abdominal pain, breast tenderness, blood clots, and abnormal bleeding. In case of overdose, it is advised to stop taking estradiol and seek medical attention.
image of a doctor in a lab doing drug, clinical research

Vivelle-Dot Novel Uses: Which Conditions Have a Clinical Trial Featuring Vivelle-Dot?

867 active clinical trials are currently in progress to assess the capacity of Vivelle-Dot to ameliorate Osteoporosis, Menstrual Absence over the past 6 months and Urogenital Atrophy.
Condition
Clinical Trials
Trial Phases
estradiol
0 Actively Recruiting
Birth Control
22 Actively Recruiting
Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2
Postmenopause
5 Actively Recruiting
Phase 2, Not Applicable
Metastatic Breast Cancer
1 Actively Recruiting
Phase 1, Phase 2
Osteoporosis, Postmenopausal
0 Actively Recruiting
Therapeutic procedure
0 Actively Recruiting
moderate to severe symptoms
0 Actively Recruiting
Hysterectomy
3 Actively Recruiting
Phase 3, Not Applicable
Breast Cancer
21 Actively Recruiting
Phase 2, Phase 1, Not Applicable
Balanitis Xerotica Obliterans
0 Actively Recruiting
Amenorrhea
1 Actively Recruiting
Phase 2
Osteoporosis
27 Actively Recruiting
Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2
Prostate Cancer
69 Actively Recruiting
Not Applicable, Phase 3, Phase 2, Phase 1, Early Phase 1
Breast
0 Actively Recruiting
Urogenital atrophy
0 Actively Recruiting
Low Testosterone
6 Actively Recruiting
Phase 4, Phase 2, Phase 1
Vasomotor System
0 Actively Recruiting
Atrophic Vaginitis
1 Actively Recruiting
Not Applicable
Hot flashes
19 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3
Hormone Replacement Therapy
0 Actively Recruiting

Vivelle-Dot Reviews: What are patients saying about Vivelle-Dot?

5Patient Review
1/20/2015
Vivelle-Dot for "Change of Life" Signs
I tried Vivelle-Dot 0.05mg after my hysterectomy, but stopped within the first day due to a severe migraine and nausea. The frequency of hot flashes may have decreased slightly, but it was not worth the side effects for me.
5Patient Review
9/17/2015
Vivelle-Dot for "Change of Life" Signs
After five years of agony, I finally found relief with this medication. I highly recommend it to other women going through menopause.
5Patient Review
7/12/2015
Vivelle-Dot for "Change of Life" Signs
I've been really pleased with this product. The patch is much smaller than other estrogen patches, and the adhesive has worked well for me.
5Patient Review
5/14/2016
Vivelle-Dot for Low Estrogen After Operation to Remove Ovaries
I've been using Vivelle Dot since it first came out, and I've tried other prescriptions in pill form from different manufacturers. None of them worked as well as the Vivelle Dot does. I think it's because the Dot is transdermal; it allows me to use a much lower dose while still getting relief.
5Patient Review
5/21/2016
Vivelle-Dot for "Change of Life" Signs
I use 1.0 mg patch and cut it in 2/3. I have a question for others who have used this treatment: has anyone else experienced itching and numbness at the site of the patch? It's very odd feeling on my left hip where I place my patch every other time (I switch hips each time). Thanks.
5Patient Review
2/26/2022
Vivelle-Dot for "Change of Life" Signs
I've been on Vivelle Dot for over 25 years and it has drastically improved my quality of life. I highly recommend it to anyone dealing with menopause symptoms.
5Patient Review
8/1/2015
Vivelle-Dot for Low Estrogen After Operation to Remove Ovaries
I am really pleased with Vivelle Dot. It has eliminated all of my menopause symptoms and I've been sleeping better, skin looks improved, even hair seems to look healthier. Very easy to use and stays on even in the shower. If possible, I would use this for the rest of my life.
5Patient Review
10/28/2021
Vivelle-Dot for "Change of Life" Signs
I've been using this medication for years with great success. The only problem I ever had was when I switched to a generic brand and it started burning my skin. I went back to the original brand and haven't had any issues since.
4.7Patient Review
10/24/2017
Vivelle-Dot for Low Estrogen After Operation to Remove Ovaries
I've been on this medication since my hysterectomy in 2000. I get migraines frequently, and I'm not sure if the patches are to blame. However, one doctor said that I might actually experience more without the patch. But when I posed this question to my pharmacist, they explained that 50% of people taking this drug report headaches and migraines. Another downside is that I have experienced a significant weight gain since being on the medication. On the bright side, though, I don't have hot flashes during the day anymore--just at night.
4.3Patient Review
12/25/2017
Vivelle-Dot for "Change of Life" Signs
Vivelle has been extremely effective in treating my symptoms. The only downside is that I sometimes experience breakthrough bleeding.
4.3Patient Review
4/4/2016
Vivelle-Dot for Post-Menopausal Osteoporosis Prevention
I've been using this product for over 18 years and it's been working great until recently. I'm 61 now and started having hot flashes and mood swings. The insurance doesn't cover this anymore, so it's quite pricey at $115 a month. Hopefully, I won't have to use it for much longer.
4Patient Review
1/12/2016
Vivelle-Dot for Low Estrogen After Operation to Remove Ovaries
Easy to use with no side effects. I would advise against using the generic form from Mylan, however. Their patch caused my ears to ring so loudly that it would wake me up from sleep.
4Patient Review
2/28/2022
Vivelle-Dot for "Change of Life" Signs
I've been using this treatment for three years and have found great success. However, in the summertime I find that the adhesive can get a little too hot and start to seep out. This causes an unsightly mess that's very difficult to remove.
3.3Patient Review
10/8/2022
Vivelle-Dot for "Change of Life" Signs
I would not recommend this patch to anyone. I used it for three years and ended up with uterine cancer as a result. My Oncologist was very clear that the patch was the cause of my tumor.
3Patient Review
2/26/2022
Vivelle-Dot for "Change of Life" Signs
This worked well enough for me.
2.3Patient Review
12/30/2014
Vivelle-Dot for Low Estrogen After Operation to Remove Ovaries
2Patient Review
3/23/2015
Vivelle-Dot for Low Estrogen After Operation to Remove Ovaries
My doctor put me on this medication after I had a total hysterectomy 7 years ago. I've been very happy not to experience menopause like my friends have. However, I did take myself off the medication for a few weeks just to see what night sweats and hot flashes were like. But I quickly went back on it afterwards.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about vivelle-dot

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long should I use Vivelle-Dot?

"Give the medication Vivelle-Dot either continuously or on a cyclic schedule, depending on whether or not the patient has an intact uterus. If the patient does have an intact uterus, then give Vivelle-Dot on a schedule of 3 weeks on the medication followed by 1 week off the medication."

Answered by AI

Is Vivelle-Dot a natural estrogen?

"The active ingredient in Vivelle-Dot, estradiol, is a form of the hormone estrogen that replaces the estrogen not produced naturally by the ovaries. It is usually applied as a long acting transdermal patch twice a week."

Answered by AI

What is the difference between estradiol patch and Vivelle-Dot?

"If you are experiencing low estrogen levels, Climara (estradiol patch) and Vivelle-Dot (estradiol patch) are both treatment options that only need to be applied once a week. These forms of estrogen may also cause fewer side effects than oral estrogen pills. Menopausal symptoms can also be relieved by using either of these patches."

Answered by AI

What is Vivelle-Dot patch used for?

"The medication is a female hormone that helps to reduce the symptoms of menopause by increasing the levels of estrogen in the body."

Answered by AI

Clinical Trials for Vivelle-Dot

Image of Altasciences in Mount Royal, Canada.

Elinzanetant for Hot Flashes

18 - 65
Female
Mount Royal, Canada
The aim of this study is to examine the relative bioavailability of elinzanetant when administered in new oral formulations (treatment B and C) after both single and multiple oral doses, compared to its administration in soft gel capsule form (treatment A). Study details include: An ambulatory screening visit within 4 weeks prior to first treatment. Participants will be admitted to the ward on Day -1 of each period. On Day 1, either treatment B or treatment C will be administered fasted in the evening, followed by blood sampling for a 24-hour pharmacokinetic (PK) profile. On Day 2, the multiple dosing starts 3 hours after a standardized dinner in the evening. After the last dosing on Day 7, a complete PK profile for 24 hours will be collected. If there are no medical objections, participants will be discharged from the study ward on Day 9 in the morning for a washout-out period of at least 10 days (240 hours after last dosing, after period 1 and 2) or, in period 3, after the follow-up examination. The total duration of the study will be approximately 10 to 12 weeks for each participant.
Phase 1
Recruiting
AltasciencesBayer
Image of Washington University School of Medicine in St Louis, United States.

Radium-223 for Prostate Cancer

18+
Male
St Louis, MO
Internal radiotherapies (radiolabeled molecules that are systemically administered and localize to sites of disease) provide cancer-ablating doses to diseased cells while sparing adjacent normal tissues. \[223Ra\]RaCl2 (Xofigo) is the first FDA-approved alpha-particle emitting radiopharmaceutical therapy (αRPT), providing a survival benefit for men with bone metastatic castration-resistant prostate cancer. Systemically administered radiotherapies distribute throughout the patient, accumulating to unknown levels at sites of disease and in radiosensitive vital organs. The whole-body distribution means that absorbed doses in the patient extend far beyond a pre-defined treatment field. There is a lack of information about αRPT distribution and localization, and this confounds treatment monitoring, complicates dose and schedule personalization, and impedes drug development. Single-photon emission computed tomography (SPECT) imaging offers a mechanism to quantify uptake; however, αRPT administered activities are significantly lower than those used with diagnostic procedures, which presents a challenge for quantitation with conventional methods. Preliminary research shows that low-count quantitative SPECT (LC-QSPECT) imaging demonstrates reliable quantitation of regional uptake for αRPTs. The purpose of this study is to demonstrate the feasibility, tolerability and performance of LC-QSPECT imaging.
Waitlist Available
Has No Placebo
Washington University School of MedicineAbhinav K Jha, Ph.D.
Image of City of Hope Medical Center in Duarte, United States.

Oral Cryotherapy for Prostate Cancer

18+
Male
Duarte, CA
This clinical trial studies whether cooling the mouth with popsicles (oral cryotherapy) decreases taste changes in prostate cancer patients receiving taxane chemotherapy. Patients receiving chemotherapy can experience a variety of side effects. Changes in the taste of food is a frequent complaint of patients receiving chemotherapy and is underreported as patients may think that it is unavoidable and not manageable. Taxane-based chemotherapy is thought to be associated with the most taste changes of any chemotherapy. Taste buds contain a specific type of cell, called gustatory cells, that are located on the surface of the tongue, the soft palate (back, muscular part of the roof of the mouth), and the upper part of the esophagus. These cells consist of five basic tastes: salty, sweet, sour, bitter, and umami (or savory). Oral cryotherapy involves cooling the mouth with ice chips, popsicles, or other cold drinks for several minutes before, during, and after chemotherapy causing the tiny blood vessels in the protective linings inside the mouth to narrow. It is thought that this narrowing will reduce blood flow to the cooled areas, thereby decreasing the amount of chemotherapy that is delivered to the fragile protective linings inside the mouth that causes the taste changes. This may be an effective way to decrease taste changes in prostate cancer patients receiving taxane chemotherapy.
Waitlist Available
Has No Placebo
City of Hope Medical CenterJeannine M Brant
Image of Erevna Innovations Inc. in Montreal, Canada.

Sculptra + Restylane for Post-Menopausal Skin Concerns

40 - 65
Female
Montreal, Canada
The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.
Phase 4
Recruiting
Erevna Innovations Inc.Andreas Nikolis, MD, PhD
Have you considered Vivelle-Dot clinical trials? We made a collection of clinical trials featuring Vivelle-Dot, we think they might fit your search criteria.Go to Trials
Image of UCLA / Jonsson Comprehensive Cancer Center in Los Angeles, United States.

Flotufolastat F 18 PET/CT for Prostate Cancer

18 - 90
Male
Los Angeles, CA
This phase II trial evaluates how well flotufolastat F 18 positron emission tomography (PET)/computed tomography (CT) imaging works to detect cancer that remains (residual) or that has come back (recurrent) after the completion of focal therapy for prostate cancer. Flotufolastat F 18 is a radioactive tracer that binds to prostate specific membrane antigen (PSMA), a protein over-expressed on prostate tumor cells. This allows for visualization of PSMA-expressing cells upon imaging. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of, in the case of this research, flotufolastat F 18. Because prostate cancer takes up flotufolastat F 18, it can be seen with PET. CT utilizes x-rays that track the body from the outside. CT images provide an exact outline of the organs and potential inflammatory tissue where it occurs in the body. The PET/CT scanner combines the PET and the CT scanners into a single device. This device combines the anatomic (body structure) information provided by the CT scan with the metabolic information obtained from the PET scan. Metabolic information means how much of the injected tracer is taken up by inflammatory tissue. Flotufolastat F 18 PET/CT imaging may be an effective and less invasive way to detect residual or recurrent disease in prostate cancer patients, compared to other methods.
Phase 2
Recruiting
UCLA / Jonsson Comprehensive Cancer CenterWayne BrisbaneBlue Earth Diagnostics
Image of UCLA / Jonsson Comprehensive Cancer Center in Los Angeles, United States.

PSMA Imaging for Prostate Cancer

18 - 90
Male
Los Angeles, CA
This early phase I trial evaluates whether a new imaging technique using flotufolastat F 18 (a type of prostate specific membrane antigen \[PSMA\] imaging agent) with positron emission tomography (PET)/computed tomography (CT) can be used to guide targeted prostate biopsies in men with prostate cancer. Flotufolastat F 18 is a radioactive imaging agent that binds to prostate tumor cells that express PSMA. This allows for visualization of PSMA-expressing tumor cells on imaging scans such as PET/CT. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, flotufolastat F 18. Because prostate cancer takes up flotufolastat F 18, it can be seen with PET. CT utilizes X-rays that track the body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in the body. The PET/CT scanner combines the PET and the CT scanners into a single device. A targeted prostate biopsy refers to using advanced imaging for guidance when taking samples (biopsies) of the prostate. This method can fuse (combine) PET/CT images with real-time ultrasound during a prostate biopsy. PSMA PET/CT scans have the potential for guiding prostate biopsies. Using image fusion technology, they can increase detection of prostate cancer by providing anatomical information and guidance during a prostate biopsy. Improved detection of prostate cancer using PSMA PET/CT guidance may better inform men and their clinicians about prostate cancer risk and management. This study attempts to determine how often prostate cancer is found when using PSMA PET/CT scan images during a biopsy versus the conventional magnetic resonance imaging-guidance.
Phase < 1
Recruiting
UCLA / Jonsson Comprehensive Cancer CenterWayne BrisbaneBlue Earth Diagnostics
Image of USC / Norris Comprehensive Cancer Center in Los Angeles, United States.

MRI-Based Machine Learning for Prostate Cancer

18+
Male
Los Angeles, CA
This clinical trial studies how well a magnetic resonance imaging (MRI)-based machine learning approach (i.e., artificial intelligence \[AI\]) works as compared to radiologist MRI readings in detecting prostate cancer. One of the current methods used to help diagnose possible prostate cancer is performing a prostate MRI. An MRI uses a magnetic field to take pictures of the body. The MRI images are examined by a radiologist. If a suspicious area is seen in the MRI, the radiologist assigns it a PIRADS score. This stands for Prostate Imaging Reporting and Data System. The PIRADS score is used to report how likely it is that a suspicious area in the prostate is cancer. The AI system has been developed also to be able to analyze prostate MRI images and detect suspicious areas in the prostate that may be cancer. The AI system's ability to diagnose aggressive prostate cancer may be similar to detection performed by experienced radiologists using the standard PIRADS system of analyzing prostate MRI.
Recruiting
Has No Placebo
USC / Norris Comprehensive Cancer CenterAndre Luis Abreu, MD
Have you considered Vivelle-Dot clinical trials? We made a collection of clinical trials featuring Vivelle-Dot, we think they might fit your search criteria.Go to Trials
Image of Mayo Clinic in Florida in Jacksonville, United States.

Virtual Reality Assistant for Prostate Cancer

Any Age
Male
Jacksonville, FL
This clinical trial tests how well a point of prostate cancer diagnosis (PPCD) virtual reality assistant (ViRA) intervention works in supporting Black men with newly diagnosed prostate cancer. Cancer is the second leading cause of death for African American/Black men, with prostate cancer leading in estimated new cancer cases and second in estimated new cancer deaths. Over 40,000 African American/Black men are diagnosed with prostate cancer annually, with 1 in 6 lifetime probability of developing prostate cancer compared to 1 in 8 probability in White men. The PPCD ViRA provides psycho-oncology support, social determinants of health navigation and emotional support for ethnically diverse African American/Black men newly diagnosed with prostate cancer using artificial intelligence and augmented reality. Using PPCD ViRA may close the prostate cancer care gap for African American/Black men across the cancer continuum and provide emotional, educational, and resource needs of this population when they are visiting a doctor about their prostate health or prostate cancer.
Waitlist Available
Has No Placebo
Mayo Clinic in FloridaFolakemi T. Odedina, PhD
Image of UCLA / Jonsson Comprehensive Cancer Center in Los Angeles, United States.

Imaging Tracer 68Ga-FAPi-46 for Cancer

18+
All Sexes
Los Angeles, CA
This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues (the biodistribution) in patients with solid tumors or hematologic (blood) cancers. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 68Ga-FAPi-46. Because some cancers take up 68Ga-FAPi-46, it can be seen with PET. CT utilizes x-rays that traverse the body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in a patient's body. Combining a PET scan with a CT scan can help make the image easier to interpret. PET/CT scans are hybrid scanners that combine both modalities into a single scan during the same examination.
Phase 1
Recruiting
UCLA / Jonsson Comprehensive Cancer CenterJeremie Calais
Have you considered Vivelle-Dot clinical trials? We made a collection of clinical trials featuring Vivelle-Dot, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security